Literature DB >> 15196240

Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

Y Luo1, H Yamada, X Chen, A A Ryan, D P Evanoff, J A Triccas, M A O'Donnell.   

Abstract

Interleukin-18 (IL-18) has been demonstrated to synergize with BCG for induction of a T-helper-type 1 (Th1) immune response. Since successful treatment of superficial bladder cancer with BCG requires proper induction of Th1 immunity, we have developed a recombinant (r) BCG strain that functionally secretes mouse (m) IL-18. This rBCG-mIL-18 strain significantly increased production of the major Th1 cytokine IFN-gamma in splenocyte cultures, at levels comparable to that elicited by control BCG plus exogenous rIL-18. IFN-gamma production by splenocytes was eliminated by addition of neutralizing anti-IL-18 antibody. Endogenous IL-12 played a favourable role whereas IL-10 played an adverse role in rBCG-mIL-18-induced IFN-gamma production. Enhanced host antimycobacterial immunity was observed in mice infected with rBCG-mIL-18 which showed less splenic enlargement and reduced bacterial load compared to control mice infected with BCG. Further, splenocytes from rBCG-mIL-18-infected mice, in response to BCG antigen, displayed increased production of IFN-gamma and GMCSF, decreased production of IL-10, elevated cellular proliferation and higher differentiation of IFN-gamma-secreting cells. rBCG-mIL-18 also enhanced BCG-induced macrophage cytotoxicity against bladder cancer MBT-2 cells in a dose-dependent manner. Neutralizing all endogenous macrophage-derived cytokines tested (IL-12, IL-18 and TNF-alpha) as well as IFN-gamma severely diminished the rBCG-mIL-18-induced macrophage cytolytic activity, indicating a critical role for these cytokines in this process. Cytokine analysis for supernatants of macrophage-BCG mixture cultures manifested higher levels of IFN-gamma and TNF-alpha in rBCG-mIL-18 cultures than in control BCG cultures. Taken together, this rBCG-mIL-18 strain augments BCG's immunostimulatory property and may serve as a better agent for bladder cancer immunotherapy and antimycobacterial immunization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196240      PMCID: PMC1809079          DOI: 10.1111/j.1365-2249.2004.02522.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  60 in total

Review 1.  Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens.

Authors:  I Sugawara
Journal:  Microbes Infect       Date:  2000-08       Impact factor: 2.700

2.  IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background.

Authors:  D Xu; V Trajkovic; D Hunter; B P Leung; K Schulz; J A Gracie; I B McInnes; F Y Liew
Journal:  Eur J Immunol       Date:  2000-11       Impact factor: 5.532

3.  Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity.

Authors:  Y Luo; X Chen; R Han; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

4.  Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18.

Authors:  S H Kim; D Cho; T S Kim
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

5.  Production of interleukin-18 in human tuberculosis.

Authors:  R Vankayalapati; B Wizel; S E Weis; B Samten; W M Girard; P F Barnes
Journal:  J Infect Dis       Date:  2000-06-29       Impact factor: 5.226

6.  Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.

Authors:  G N Thalmann; A Sermier; C Rentsch; K Möhrle; M G Cecchini; U E Studer
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

7.  Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas.

Authors:  U Elsässer-Beile; O Gutzeit; S Bauer; A Katzenwadel; W Schultze-Seemann; U Wetterauer
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

8.  Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity.

Authors:  Y Luo; X Chen; A Szilvasi; M A O'Donnell
Journal:  Mol Immunol       Date:  2000-06       Impact factor: 4.407

9.  New use of BCG for recombinant vaccines.

Authors:  C K Stover; V F de la Cruz; T R Fuerst; J E Burlein; L A Benson; L T Bennett; G P Bansal; J F Young; M H Lee; G F Hatfull
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

10.  Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.

Authors:  R De Jager; P Guinan; D Lamm; O Khanna; S Brosman; J De Kernion; R Williams; C Richardson; L Muenz; D Reitsma
Journal:  Urology       Date:  1991-12       Impact factor: 2.649

View more
  29 in total

Review 1.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

Review 2.  Evolving immunotherapy strategies in urothelial cancer.

Authors:  Sam J Brancato; Keidren Lewi; Piyush K Agarwal
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

Review 3.  Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.

Authors:  Akhil Muthigi; Arvin K George; Sam J Brancato; Piyush K Agarwal
Journal:  Ther Adv Urol       Date:  2016-02-09

4.  Identification and characterization of an SKN7 homologue in Cryptococcus neoformans.

Authors:  F L Wormley; G Heinrich; J L Miller; J R Perfect; G M Cox
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Y Luo; R Han; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2010-02-10       Impact factor: 4.330

6.  Urinary bladder epithelium antigen induces CD8+ T cell tolerance, activation, and autoimmune response.

Authors:  Wujiang Liu; David P Evanoff; Xiaohong Chen; Yi Luo
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

7.  Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells.

Authors:  Y Luo; H Yamada; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

8.  Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection.

Authors:  Anthony A Ryan; Joanne M Spratt; Warwick J Britton; James A Triccas
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

Review 9.  Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Yi Luo; Matthew J Knudson
Journal:  Clin Dev Immunol       Date:  2010-09-01

10.  Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.

Authors:  James A Triccas; Elena Shklovskaya; Joanne Spratt; Anthony A Ryan; Umaimainthan Palendira; Barbara Fazekas de St Groth; Warwick J Britton
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.